GlassScriptPhysician profile
David Marc Sheinbein
NPI 1568489193
$4,132.78
in general payments reported to CMS, 2019-2025
24 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2021: $12.37 · 2022: $66.09 · 2023: $465 · 2024: $987 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.62 |
| Education | $567.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $421.75 | 2024-2025 | Tremfya |
| Abbvie INC. | $381.83 | 2022-2025 | Skyrizi, Rinvoq, Humira |
| Leo Pharma INC. | $366.05 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $347.67 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $322.20 | 2024-2025 | Opzelura |
| Ucb, INC. | $318.73 | 2021-2025 | Bimzelx |
| Pfizer INC. | $296.40 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $235.99 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $209.57 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $205.71 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $195.40 | 2024-2025 | |
| Amgen INC. | $190.57 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $109.88 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $99.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.82 | 2023-2025 | Spevigo, Cyltezo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.65 | 2025 | |
| Lilly USA, LLC | $54.29 | 2024-2025 | Ebglyss, Taltz |
| Convatec INC. | $47.95 | 2025 | |
| Strata Skin Sciences, INC. | $32.97 | 2025 | Xtrac |
| Alnylam Pharmaceuticals INC. | $29.72 | 2025 | Givlaari |
| Organon LLC | $24.99 | 2025 | Vtama |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Dermavant Sciences, INC. | $21.64 | 2024 | Vtama |
| Fresenius Kabi USA, LLC | $14.50 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sheinbein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.